Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.
杭州九源基因生物醫藥股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 2566)

POLL RESULTS OF THE FIRST EXTRAORDINARY GENERAL MEETING OF 2026 HELD ON FRIDAY, SEPTEMBER 18, 2026

The board (the "**Board**") of directors ("**Directors**") of Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (杭州九源基因生物醫藥股份有限公司) (the "**Company**") is pleased to announce the poll results of the first extraordinary general meeting of 2026 (the "**EGM**") held on Friday, September 18, 2026.

For details of the resolutions considered at the EGM, the shareholders of the Company (the "**Shareholders**") may refer to the notice of the EGM and the Company's circular (the "**Circular**"), both dated August 31, 2026. Unless otherwise defined, capitalized terms in this announcement shall have the same meanings as those defined in the Circular.

CONVENING AND ATTENDANCE OF THE EGM

The EGM was held as an on-site meeting at Conference Room 3, No. 23, Eighth Street, Baiyang Street, Qiantang District, Hangzhou, Zhejiang Province, PRC on Friday, September 18, 2026.

The EGM was convened by the Board and hosted by Mr. Fu Hang, the chairman of the Board. All the Directors attended the EGM, either in person or online.

The convention of the EGM was in compliance with the requirements of the applicable PRC laws and regulations, the Listing Rules and the Articles of Association. All the proposed resolutions as set out in the notice of the EGM were tabled before the EGM for Shareholders' consideration and approval, and were put to vote by way of poll.

To the best knowledge of the Board having made all reasonable inquiries, (i) there was no restriction on any Shareholder casting votes on any proposed resolution at the EGM; (ii) no Shareholder has a material interest in the matters considered at the EGM and was required under the Listing Rules to abstain from voting at the EGM; (iii) there were no Shares entitling the holders to attend and abstain from voting in favour of any resolution proposed at the EGM as set out in Rule 13.40 of the Listing Rules; and (iv) no party has stated any intention in the Circular to vote against or abstain from voting on any resolution proposed at the EGM.

POLL RESULTS OF THE EGM

As of the date of the EGM, the total number of issued Shares and Shares entitling the holders to attend and vote for or against the resolutions proposed at the EGM was 239,824,400 (excluding 5,574,400 treasury Shares at the date of this announcement), all of which were H Shares. As of the date of the EGM, there were (i) 5,574,400 treasury Shares held by the Company (including any treasury Shares held or deposited with the Central Clearing and Settlement System established and operated by Hong Kong Securities Clearing Company Limited) and as such no voting rights of treasury Shares have been exercised at the EGM; and (ii) no Shares repurchased by the Company which are pending cancellation. The number of Shareholder and authorized proxy who attended the EGM was one. Shareholder and authorized proxy holding an aggregate of 110,601,750 Shares attended the EGM, representing approximately 46.12% of the total number of issued Shares with voting rights (excluding treasury Shares).

At the EGM, the following resolutions were considered and passed by registered poll and the poll results are set out as follows:

Ordinary Resolution		**Number of Votes (%)**		
		For	**Against**	**Abstain**
1.	To consider and approve the Proposed Changes in Use of Proceeds.	110,601,750 (100.00%)	0 (0.00%)	0 (0.00%)
Special Resolution		**Number of Votes (%)**		
		For	**Against**	**Abstain**
2.	To consider and approve the Proposed Amendments to the Articles of Association.	110,601,750 (100.00%)	0 (0.00%)	0 (0.00%)

As a majority of the votes were cast in favor of the resolution number 1, such resolution was duly passed as an ordinary resolution. As more than two-thirds of the votes were cast in favor of the resolution numbered 2, such resolution was duly passed as a special resolution.

AMENDMENTS TO THE ARTICLES OF ASSOCIATION

As the resolution numbered 2 regarding the amendments to the Articles of Association was approved at the EGM, the amendments to the Articles of Association took effect after the adoption of resolution 2 at the EGM on September 18, 2026. The Company will undertake necessary filing procedures in Hong Kong and the PRC in due course. The full text of the amended Articles of Association will be published on the websites of the Stock Exchange at www.hkexnews.hk and the Company at www.china-gene.com. Shareholders of the Company should be aware that the English version of the Articles of Association is a translation from the Chinese version. The Chinese version of the Articles of Association shall prevail in the case of discrepancies and/or inconsistencies between the two versions.

SCRUTINEERS

The H Share Registrar of the Company, Computershare Hong Kong Investor Services Limited and two Shareholders' representatives served as the scrutineers of the EGM for scrutinizing and counting votes.

By order of the Board
Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.
杭州九源基因生物醫藥股份有限公司
FU Hang
Executive Director, Chairman of the Board and General Manager

Hangzhou, the PRC, September 18, 2026

As of the date of this announcement, the Board comprises (i) Mr. Fu Hang (傅航) and Mr. Zhou Wei (周偉) as executive directors; (ii) Mr. Wu Shihang (吳詩航), Mr. Albert Esteve Cruella, Mr. Fei Junjie (費俊傑) and Ms. Yan Weiting (嚴瑋婷) as non-executive directors; and (iii) Mr. Zhou Zhihui (周智慧), Ms. Ho Mei Yi (何美儀), Dr. Zhou Demin (周德敏) and Dr. Huang Wenli (黃文禮) as independent non-executive directors; and (iv) Mr. Xu Feihu (徐飛虎) as an employee representative director.